Dechra Pharmaceuticals PLC
Dechra Pharmaceuticals PLC (DCHPF) Stock Competitors & Peer Comparison
See (DCHPF) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Pharmaceuticals Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| DCHPF | $46.90 | -0.21% | 5.3B | -151.29 | -$0.31 | N/A |
| ALBHF | $0.61 | -5.41% | 9.8B | 30.32 | $0.02 | N/A |
| ALBBY | $12.12 | +20.60% | 9.8B | 34.63 | $0.35 | N/A |
| RADLY | $4.25 | -4.71% | 7.4B | 28.33 | $0.15 | +1.92% |
| MSMKF | $18.17 | +0.00% | 7.2B | 19.75 | $0.92 | +1.80% |
| RGEDF | $31.00 | +0.00% | 5.7B | 8.68 | $3.57 | +4.19% |
| GEDSF | $24.85 | +0.00% | 4.5B | 10.71 | $2.32 | +5.69% |
| TSUSF | $17.25 | +0.00% | 4.2B | 41.07 | $0.42 | +5.95% |
| CLCGY | $35.16 | +0.04% | 4.1B | 21.84 | $1.61 | +2.46% |
| CSMYF | $48.27 | +0.00% | 3.8B | 19.23 | $2.51 | +1.04% |
Stock Comparison
DCHPF vs ALBHF Comparison April 2026
DCHPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCHPF stands at 5.3B. In comparison, ALBHF has a market cap of 9.8B. Regarding current trading prices, DCHPF is priced at $46.90, while ALBHF trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCHPF currently has a P/E ratio of -151.29, whereas ALBHF's P/E ratio is 30.32. In terms of profitability, DCHPF's ROE is -0.04%, compared to ALBHF's ROE of +0.18%. Regarding short-term risk, DCHPF is less volatile compared to ALBHF. This indicates potentially lower risk in terms of short-term price fluctuations for DCHPF.Check ALBHF's competition here
DCHPF vs ALBBY Comparison April 2026
DCHPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCHPF stands at 5.3B. In comparison, ALBBY has a market cap of 9.8B. Regarding current trading prices, DCHPF is priced at $46.90, while ALBBY trades at $12.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCHPF currently has a P/E ratio of -151.29, whereas ALBBY's P/E ratio is 34.63. In terms of profitability, DCHPF's ROE is -0.04%, compared to ALBBY's ROE of +0.18%. Regarding short-term risk, DCHPF is less volatile compared to ALBBY. This indicates potentially lower risk in terms of short-term price fluctuations for DCHPF.Check ALBBY's competition here
DCHPF vs RADLY Comparison April 2026
DCHPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCHPF stands at 5.3B. In comparison, RADLY has a market cap of 7.4B. Regarding current trading prices, DCHPF is priced at $46.90, while RADLY trades at $4.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCHPF currently has a P/E ratio of -151.29, whereas RADLY's P/E ratio is 28.33. In terms of profitability, DCHPF's ROE is -0.04%, compared to RADLY's ROE of +0.19%. Regarding short-term risk, DCHPF is less volatile compared to RADLY. This indicates potentially lower risk in terms of short-term price fluctuations for DCHPF.Check RADLY's competition here
DCHPF vs MSMKF Comparison April 2026
DCHPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCHPF stands at 5.3B. In comparison, MSMKF has a market cap of 7.2B. Regarding current trading prices, DCHPF is priced at $46.90, while MSMKF trades at $18.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCHPF currently has a P/E ratio of -151.29, whereas MSMKF's P/E ratio is 19.75. In terms of profitability, DCHPF's ROE is -0.04%, compared to MSMKF's ROE of +0.11%. Regarding short-term risk, DCHPF is less volatile compared to MSMKF. This indicates potentially lower risk in terms of short-term price fluctuations for DCHPF.Check MSMKF's competition here
DCHPF vs RGEDF Comparison April 2026
DCHPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCHPF stands at 5.3B. In comparison, RGEDF has a market cap of 5.7B. Regarding current trading prices, DCHPF is priced at $46.90, while RGEDF trades at $31.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCHPF currently has a P/E ratio of -151.29, whereas RGEDF's P/E ratio is 8.68. In terms of profitability, DCHPF's ROE is -0.04%, compared to RGEDF's ROE of +0.17%. Regarding short-term risk, DCHPF and RGEDF have similar daily volatility (0.00).Check RGEDF's competition here
DCHPF vs GEDSF Comparison April 2026
DCHPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCHPF stands at 5.3B. In comparison, GEDSF has a market cap of 4.5B. Regarding current trading prices, DCHPF is priced at $46.90, while GEDSF trades at $24.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCHPF currently has a P/E ratio of -151.29, whereas GEDSF's P/E ratio is 10.71. In terms of profitability, DCHPF's ROE is -0.04%, compared to GEDSF's ROE of +0.17%. Regarding short-term risk, DCHPF and GEDSF have similar daily volatility (0.00).Check GEDSF's competition here
DCHPF vs TSUSF Comparison April 2026
DCHPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCHPF stands at 5.3B. In comparison, TSUSF has a market cap of 4.2B. Regarding current trading prices, DCHPF is priced at $46.90, while TSUSF trades at $17.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCHPF currently has a P/E ratio of -151.29, whereas TSUSF's P/E ratio is 41.07. In terms of profitability, DCHPF's ROE is -0.04%, compared to TSUSF's ROE of +0.12%. Regarding short-term risk, DCHPF and TSUSF have similar daily volatility (0.00).Check TSUSF's competition here
DCHPF vs CLCGY Comparison April 2026
DCHPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCHPF stands at 5.3B. In comparison, CLCGY has a market cap of 4.1B. Regarding current trading prices, DCHPF is priced at $46.90, while CLCGY trades at $35.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCHPF currently has a P/E ratio of -151.29, whereas CLCGY's P/E ratio is 21.84. In terms of profitability, DCHPF's ROE is -0.04%, compared to CLCGY's ROE of +0.48%. Regarding short-term risk, DCHPF is less volatile compared to CLCGY. This indicates potentially lower risk in terms of short-term price fluctuations for DCHPF.Check CLCGY's competition here
DCHPF vs CSMYF Comparison April 2026
DCHPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCHPF stands at 5.3B. In comparison, CSMYF has a market cap of 3.8B. Regarding current trading prices, DCHPF is priced at $46.90, while CSMYF trades at $48.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCHPF currently has a P/E ratio of -151.29, whereas CSMYF's P/E ratio is 19.23. In terms of profitability, DCHPF's ROE is -0.04%, compared to CSMYF's ROE of +0.12%. Regarding short-term risk, DCHPF is less volatile compared to CSMYF. This indicates potentially lower risk in terms of short-term price fluctuations for DCHPF.Check CSMYF's competition here
DCHPF vs WLCGF Comparison April 2026
DCHPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCHPF stands at 5.3B. In comparison, WLCGF has a market cap of 3.4B. Regarding current trading prices, DCHPF is priced at $46.90, while WLCGF trades at $16.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCHPF currently has a P/E ratio of -151.29, whereas WLCGF's P/E ratio is 19.54. In terms of profitability, DCHPF's ROE is -0.04%, compared to WLCGF's ROE of +0.08%. Regarding short-term risk, DCHPF and WLCGF have similar daily volatility (0.00).Check WLCGF's competition here
DCHPF vs SDGCF Comparison April 2026
DCHPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCHPF stands at 5.3B. In comparison, SDGCF has a market cap of 3.3B. Regarding current trading prices, DCHPF is priced at $46.90, while SDGCF trades at $28.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCHPF currently has a P/E ratio of -151.29, whereas SDGCF's P/E ratio is 17.40. In terms of profitability, DCHPF's ROE is -0.04%, compared to SDGCF's ROE of +0.11%. Regarding short-term risk, DCHPF and SDGCF have similar daily volatility (0.00).Check SDGCF's competition here
DCHPF vs SGIPF Comparison April 2026
DCHPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCHPF stands at 5.3B. In comparison, SGIPF has a market cap of 2.9B. Regarding current trading prices, DCHPF is priced at $46.90, while SGIPF trades at $16.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCHPF currently has a P/E ratio of -151.29, whereas SGIPF's P/E ratio is 20.11. In terms of profitability, DCHPF's ROE is -0.04%, compared to SGIPF's ROE of +0.10%. Regarding short-term risk, DCHPF and SGIPF have similar daily volatility (0.00).Check SGIPF's competition here
DCHPF vs HTSUY Comparison April 2026
DCHPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCHPF stands at 5.3B. In comparison, HTSUY has a market cap of 1.9B. Regarding current trading prices, DCHPF is priced at $46.90, while HTSUY trades at $6.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCHPF currently has a P/E ratio of -151.29, whereas HTSUY's P/E ratio is N/A. In terms of profitability, DCHPF's ROE is -0.04%, compared to HTSUY's ROE of +0.07%. Regarding short-term risk, DCHPF and HTSUY have similar daily volatility (0.00).Check HTSUY's competition here
DCHPF vs SHPPF Comparison April 2026
DCHPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCHPF stands at 5.3B. In comparison, SHPPF has a market cap of 919M. Regarding current trading prices, DCHPF is priced at $46.90, while SHPPF trades at $45.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCHPF currently has a P/E ratio of -151.29, whereas SHPPF's P/E ratio is -20.92. In terms of profitability, DCHPF's ROE is -0.04%, compared to SHPPF's ROE of -0.08%. Regarding short-term risk, DCHPF is less volatile compared to SHPPF. This indicates potentially lower risk in terms of short-term price fluctuations for DCHPF.Check SHPPF's competition here
DCHPF vs SAEYY Comparison April 2026
DCHPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCHPF stands at 5.3B. In comparison, SAEYY has a market cap of 804.4M. Regarding current trading prices, DCHPF is priced at $46.90, while SAEYY trades at $4.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCHPF currently has a P/E ratio of -151.29, whereas SAEYY's P/E ratio is -19.05. In terms of profitability, DCHPF's ROE is -0.04%, compared to SAEYY's ROE of -0.08%. Regarding short-term risk, DCHPF is less volatile compared to SAEYY. This indicates potentially lower risk in terms of short-term price fluctuations for DCHPF.Check SAEYY's competition here
DCHPF vs BJTRF Comparison April 2026
DCHPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCHPF stands at 5.3B. In comparison, BJTRF has a market cap of 542.8M. Regarding current trading prices, DCHPF is priced at $46.90, while BJTRF trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCHPF currently has a P/E ratio of -151.29, whereas BJTRF's P/E ratio is 8.10. In terms of profitability, DCHPF's ROE is -0.04%, compared to BJTRF's ROE of +0.02%. Regarding short-term risk, DCHPF and BJTRF have similar daily volatility (0.00).Check BJTRF's competition here
DCHPF vs ZRSEF Comparison April 2026
DCHPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCHPF stands at 5.3B. In comparison, ZRSEF has a market cap of 497.5M. Regarding current trading prices, DCHPF is priced at $46.90, while ZRSEF trades at $10.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCHPF currently has a P/E ratio of -151.29, whereas ZRSEF's P/E ratio is -1.81. In terms of profitability, DCHPF's ROE is -0.04%, compared to ZRSEF's ROE of -0.30%. Regarding short-term risk, DCHPF is less volatile compared to ZRSEF. This indicates potentially lower risk in terms of short-term price fluctuations for DCHPF.Check ZRSEF's competition here
DCHPF vs MYCOF Comparison April 2026
DCHPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCHPF stands at 5.3B. In comparison, MYCOF has a market cap of 81.4M. Regarding current trading prices, DCHPF is priced at $46.90, while MYCOF trades at $1.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCHPF currently has a P/E ratio of -151.29, whereas MYCOF's P/E ratio is 0.87. In terms of profitability, DCHPF's ROE is -0.04%, compared to MYCOF's ROE of -0.15%. Regarding short-term risk, DCHPF is less volatile compared to MYCOF. This indicates potentially lower risk in terms of short-term price fluctuations for DCHPF.Check MYCOF's competition here
DCHPF vs NVACF Comparison April 2026
DCHPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCHPF stands at 5.3B. In comparison, NVACF has a market cap of 78.5M. Regarding current trading prices, DCHPF is priced at $46.90, while NVACF trades at $1.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCHPF currently has a P/E ratio of -151.29, whereas NVACF's P/E ratio is 31.60. In terms of profitability, DCHPF's ROE is -0.04%, compared to NVACF's ROE of +0.06%. Regarding short-term risk, DCHPF is less volatile compared to NVACF. This indicates potentially lower risk in terms of short-term price fluctuations for DCHPF.Check NVACF's competition here
DCHPF vs FFLWF Comparison April 2026
DCHPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCHPF stands at 5.3B. In comparison, FFLWF has a market cap of 5.4M. Regarding current trading prices, DCHPF is priced at $46.90, while FFLWF trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCHPF currently has a P/E ratio of -151.29, whereas FFLWF's P/E ratio is -0.08. In terms of profitability, DCHPF's ROE is -0.04%, compared to FFLWF's ROE of -0.97%. Regarding short-term risk, DCHPF is less volatile compared to FFLWF. This indicates potentially lower risk in terms of short-term price fluctuations for DCHPF.Check FFLWF's competition here
DCHPF vs HEWA Comparison April 2026
DCHPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCHPF stands at 5.3B. In comparison, HEWA has a market cap of 5.1M. Regarding current trading prices, DCHPF is priced at $46.90, while HEWA trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCHPF currently has a P/E ratio of -151.29, whereas HEWA's P/E ratio is -4.00. In terms of profitability, DCHPF's ROE is -0.04%, compared to HEWA's ROE of -0.08%. Regarding short-term risk, DCHPF is less volatile compared to HEWA. This indicates potentially lower risk in terms of short-term price fluctuations for DCHPF.Check HEWA's competition here
DCHPF vs PNPL Comparison April 2026
DCHPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCHPF stands at 5.3B. In comparison, PNPL has a market cap of 3.1M. Regarding current trading prices, DCHPF is priced at $46.90, while PNPL trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCHPF currently has a P/E ratio of -151.29, whereas PNPL's P/E ratio is -4.20. In terms of profitability, DCHPF's ROE is -0.04%, compared to PNPL's ROE of +0.10%. Regarding short-term risk, DCHPF and PNPL have similar daily volatility (0.00).Check PNPL's competition here
DCHPF vs SYDRF Comparison April 2026
DCHPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCHPF stands at 5.3B. In comparison, SYDRF has a market cap of 2.9M. Regarding current trading prices, DCHPF is priced at $46.90, while SYDRF trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCHPF currently has a P/E ratio of -151.29, whereas SYDRF's P/E ratio is 10.00. In terms of profitability, DCHPF's ROE is -0.04%, compared to SYDRF's ROE of -0.42%. Regarding short-term risk, DCHPF and SYDRF have similar daily volatility (0.00).Check SYDRF's competition here
DCHPF vs GABLF Comparison April 2026
DCHPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCHPF stands at 5.3B. In comparison, GABLF has a market cap of 2.7M. Regarding current trading prices, DCHPF is priced at $46.90, while GABLF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCHPF currently has a P/E ratio of -151.29, whereas GABLF's P/E ratio is -0.04. In terms of profitability, DCHPF's ROE is -0.04%, compared to GABLF's ROE of +2.91%. Regarding short-term risk, DCHPF and GABLF have similar daily volatility (0.00).Check GABLF's competition here
DCHPF vs ETBI Comparison April 2026
DCHPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCHPF stands at 5.3B. In comparison, ETBI has a market cap of 2.1M. Regarding current trading prices, DCHPF is priced at $46.90, while ETBI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCHPF currently has a P/E ratio of -151.29, whereas ETBI's P/E ratio is -0.10. In terms of profitability, DCHPF's ROE is -0.04%, compared to ETBI's ROE of +0.41%. Regarding short-term risk, DCHPF is less volatile compared to ETBI. This indicates potentially lower risk in terms of short-term price fluctuations for DCHPF.Check ETBI's competition here
DCHPF vs RLLVF Comparison April 2026
DCHPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCHPF stands at 5.3B. In comparison, RLLVF has a market cap of 2M. Regarding current trading prices, DCHPF is priced at $46.90, while RLLVF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCHPF currently has a P/E ratio of -151.29, whereas RLLVF's P/E ratio is -0.60. In terms of profitability, DCHPF's ROE is -0.04%, compared to RLLVF's ROE of +2.21%. Regarding short-term risk, DCHPF is less volatile compared to RLLVF. This indicates potentially lower risk in terms of short-term price fluctuations for DCHPF.Check RLLVF's competition here
DCHPF vs IWINF Comparison April 2026
DCHPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCHPF stands at 5.3B. In comparison, IWINF has a market cap of 1.7M. Regarding current trading prices, DCHPF is priced at $46.90, while IWINF trades at $0.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCHPF currently has a P/E ratio of -151.29, whereas IWINF's P/E ratio is -0.06. In terms of profitability, DCHPF's ROE is -0.04%, compared to IWINF's ROE of -0.21%. Regarding short-term risk, DCHPF and IWINF have similar daily volatility (0.00).Check IWINF's competition here
DCHPF vs LGNZZ Comparison April 2026
DCHPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCHPF stands at 5.3B. In comparison, LGNZZ has a market cap of 1.4M. Regarding current trading prices, DCHPF is priced at $46.90, while LGNZZ trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCHPF currently has a P/E ratio of -151.29, whereas LGNZZ's P/E ratio is N/A. In terms of profitability, DCHPF's ROE is -0.04%, compared to LGNZZ's ROE of +0.14%. Regarding short-term risk, DCHPF and LGNZZ have similar daily volatility (0.00).Check LGNZZ's competition here
DCHPF vs NUTTQ Comparison April 2026
DCHPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCHPF stands at 5.3B. In comparison, NUTTQ has a market cap of 1.1M. Regarding current trading prices, DCHPF is priced at $46.90, while NUTTQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCHPF currently has a P/E ratio of -151.29, whereas NUTTQ's P/E ratio is N/A. In terms of profitability, DCHPF's ROE is -0.04%, compared to NUTTQ's ROE of +3.01%. Regarding short-term risk, DCHPF is less volatile compared to NUTTQ. This indicates potentially lower risk in terms of short-term price fluctuations for DCHPF.Check NUTTQ's competition here
DCHPF vs CAFS Comparison April 2026
DCHPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCHPF stands at 5.3B. In comparison, CAFS has a market cap of 939.1K. Regarding current trading prices, DCHPF is priced at $46.90, while CAFS trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCHPF currently has a P/E ratio of -151.29, whereas CAFS's P/E ratio is 0.49. In terms of profitability, DCHPF's ROE is -0.04%, compared to CAFS's ROE of +1.94%. Regarding short-term risk, DCHPF is less volatile compared to CAFS. This indicates potentially lower risk in terms of short-term price fluctuations for DCHPF.Check CAFS's competition here
DCHPF vs LGNYZ Comparison April 2026
DCHPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCHPF stands at 5.3B. In comparison, LGNYZ has a market cap of 737.8K. Regarding current trading prices, DCHPF is priced at $46.90, while LGNYZ trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCHPF currently has a P/E ratio of -151.29, whereas LGNYZ's P/E ratio is N/A. In terms of profitability, DCHPF's ROE is -0.04%, compared to LGNYZ's ROE of +0.14%. Regarding short-term risk, DCHPF and LGNYZ have similar daily volatility (0.00).Check LGNYZ's competition here
DCHPF vs CNBI Comparison April 2026
DCHPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCHPF stands at 5.3B. In comparison, CNBI has a market cap of 686.8K. Regarding current trading prices, DCHPF is priced at $46.90, while CNBI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCHPF currently has a P/E ratio of -151.29, whereas CNBI's P/E ratio is N/A. In terms of profitability, DCHPF's ROE is -0.04%, compared to CNBI's ROE of +0.17%. Regarding short-term risk, DCHPF is less volatile compared to CNBI. This indicates potentially lower risk in terms of short-term price fluctuations for DCHPF.Check CNBI's competition here
DCHPF vs RADCQ Comparison April 2026
DCHPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCHPF stands at 5.3B. In comparison, RADCQ has a market cap of 559.7K. Regarding current trading prices, DCHPF is priced at $46.90, while RADCQ trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCHPF currently has a P/E ratio of -151.29, whereas RADCQ's P/E ratio is -0.00. In terms of profitability, DCHPF's ROE is -0.04%, compared to RADCQ's ROE of +3.01%. Regarding short-term risk, DCHPF is less volatile compared to RADCQ. This indicates potentially lower risk in terms of short-term price fluctuations for DCHPF.Check RADCQ's competition here
DCHPF vs MMDCF Comparison April 2026
DCHPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCHPF stands at 5.3B. In comparison, MMDCF has a market cap of 541.2K. Regarding current trading prices, DCHPF is priced at $46.90, while MMDCF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCHPF currently has a P/E ratio of -151.29, whereas MMDCF's P/E ratio is N/A. In terms of profitability, DCHPF's ROE is -0.04%, compared to MMDCF's ROE of N/A. Regarding short-term risk, DCHPF and MMDCF have similar daily volatility (0.00).Check MMDCF's competition here
DCHPF vs BIEI Comparison April 2026
DCHPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCHPF stands at 5.3B. In comparison, BIEI has a market cap of 500K. Regarding current trading prices, DCHPF is priced at $46.90, while BIEI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCHPF currently has a P/E ratio of -151.29, whereas BIEI's P/E ratio is -0.05. In terms of profitability, DCHPF's ROE is -0.04%, compared to BIEI's ROE of +0.01%. Regarding short-term risk, DCHPF is less volatile compared to BIEI. This indicates potentially lower risk in terms of short-term price fluctuations for DCHPF.Check BIEI's competition here
DCHPF vs AEGY Comparison April 2026
DCHPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCHPF stands at 5.3B. In comparison, AEGY has a market cap of 411.2K. Regarding current trading prices, DCHPF is priced at $46.90, while AEGY trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCHPF currently has a P/E ratio of -151.29, whereas AEGY's P/E ratio is N/A. In terms of profitability, DCHPF's ROE is -0.04%, compared to AEGY's ROE of +0.00%. Regarding short-term risk, DCHPF and AEGY have similar daily volatility (0.00).Check AEGY's competition here
DCHPF vs IPAH Comparison April 2026
DCHPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCHPF stands at 5.3B. In comparison, IPAH has a market cap of 270.8K. Regarding current trading prices, DCHPF is priced at $46.90, while IPAH trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCHPF currently has a P/E ratio of -151.29, whereas IPAH's P/E ratio is -0.05. In terms of profitability, DCHPF's ROE is -0.04%, compared to IPAH's ROE of -0.82%. Regarding short-term risk, DCHPF is less volatile compared to IPAH. This indicates potentially lower risk in terms of short-term price fluctuations for DCHPF.Check IPAH's competition here
DCHPF vs IMMB Comparison April 2026
DCHPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCHPF stands at 5.3B. In comparison, IMMB has a market cap of 115K. Regarding current trading prices, DCHPF is priced at $46.90, while IMMB trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCHPF currently has a P/E ratio of -151.29, whereas IMMB's P/E ratio is N/A. In terms of profitability, DCHPF's ROE is -0.04%, compared to IMMB's ROE of -0.09%. Regarding short-term risk, DCHPF is less volatile compared to IMMB. This indicates potentially lower risk in terms of short-term price fluctuations for DCHPF.Check IMMB's competition here
DCHPF vs FOGCF Comparison April 2026
DCHPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCHPF stands at 5.3B. In comparison, FOGCF has a market cap of 97.2K. Regarding current trading prices, DCHPF is priced at $46.90, while FOGCF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCHPF currently has a P/E ratio of -151.29, whereas FOGCF's P/E ratio is N/A. In terms of profitability, DCHPF's ROE is -0.04%, compared to FOGCF's ROE of +3.99%. Regarding short-term risk, DCHPF is less volatile compared to FOGCF. This indicates potentially lower risk in terms of short-term price fluctuations for DCHPF.Check FOGCF's competition here
DCHPF vs MDIN Comparison April 2026
DCHPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCHPF stands at 5.3B. In comparison, MDIN has a market cap of 90.3K. Regarding current trading prices, DCHPF is priced at $46.90, while MDIN trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCHPF currently has a P/E ratio of -151.29, whereas MDIN's P/E ratio is N/A. In terms of profitability, DCHPF's ROE is -0.04%, compared to MDIN's ROE of +0.36%. Regarding short-term risk, DCHPF is less volatile compared to MDIN. This indicates potentially lower risk in terms of short-term price fluctuations for DCHPF.Check MDIN's competition here
DCHPF vs OXIHF Comparison April 2026
DCHPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCHPF stands at 5.3B. In comparison, OXIHF has a market cap of 72K. Regarding current trading prices, DCHPF is priced at $46.90, while OXIHF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCHPF currently has a P/E ratio of -151.29, whereas OXIHF's P/E ratio is N/A. In terms of profitability, DCHPF's ROE is -0.04%, compared to OXIHF's ROE of +3.30%. Regarding short-term risk, DCHPF is less volatile compared to OXIHF. This indicates potentially lower risk in terms of short-term price fluctuations for DCHPF.Check OXIHF's competition here
DCHPF vs LGNXZ Comparison April 2026
DCHPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCHPF stands at 5.3B. In comparison, LGNXZ has a market cap of 57.8K. Regarding current trading prices, DCHPF is priced at $46.90, while LGNXZ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCHPF currently has a P/E ratio of -151.29, whereas LGNXZ's P/E ratio is N/A. In terms of profitability, DCHPF's ROE is -0.04%, compared to LGNXZ's ROE of +0.14%. Regarding short-term risk, DCHPF and LGNXZ have similar daily volatility (0.00).Check LGNXZ's competition here
DCHPF vs HADV Comparison April 2026
DCHPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCHPF stands at 5.3B. In comparison, HADV has a market cap of 48.3K. Regarding current trading prices, DCHPF is priced at $46.90, while HADV trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCHPF currently has a P/E ratio of -151.29, whereas HADV's P/E ratio is N/A. In terms of profitability, DCHPF's ROE is -0.04%, compared to HADV's ROE of +0.18%. Regarding short-term risk, DCHPF and HADV have similar daily volatility (0.00).Check HADV's competition here
DCHPF vs AXMP Comparison April 2026
DCHPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCHPF stands at 5.3B. In comparison, AXMP has a market cap of 40.9K. Regarding current trading prices, DCHPF is priced at $46.90, while AXMP trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCHPF currently has a P/E ratio of -151.29, whereas AXMP's P/E ratio is 0.05. In terms of profitability, DCHPF's ROE is -0.04%, compared to AXMP's ROE of N/A. Regarding short-term risk, DCHPF and AXMP have similar daily volatility (0.00).Check AXMP's competition here
DCHPF vs LGNDZ Comparison April 2026
DCHPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCHPF stands at 5.3B. In comparison, LGNDZ has a market cap of 36.1K. Regarding current trading prices, DCHPF is priced at $46.90, while LGNDZ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCHPF currently has a P/E ratio of -151.29, whereas LGNDZ's P/E ratio is N/A. In terms of profitability, DCHPF's ROE is -0.04%, compared to LGNDZ's ROE of +0.14%. Regarding short-term risk, DCHPF is less volatile compared to LGNDZ. This indicates potentially lower risk in terms of short-term price fluctuations for DCHPF.Check LGNDZ's competition here
DCHPF vs DECN Comparison April 2026
DCHPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCHPF stands at 5.3B. In comparison, DECN has a market cap of 35.5K. Regarding current trading prices, DCHPF is priced at $46.90, while DECN trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCHPF currently has a P/E ratio of -151.29, whereas DECN's P/E ratio is N/A. In terms of profitability, DCHPF's ROE is -0.04%, compared to DECN's ROE of -103.89%. Regarding short-term risk, DCHPF and DECN have similar daily volatility (0.00).Check DECN's competition here
DCHPF vs SPPH Comparison April 2026
DCHPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCHPF stands at 5.3B. In comparison, SPPH has a market cap of 29.4K. Regarding current trading prices, DCHPF is priced at $46.90, while SPPH trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCHPF currently has a P/E ratio of -151.29, whereas SPPH's P/E ratio is -0.03. In terms of profitability, DCHPF's ROE is -0.04%, compared to SPPH's ROE of -0.50%. Regarding short-term risk, DCHPF is less volatile compared to SPPH. This indicates potentially lower risk in terms of short-term price fluctuations for DCHPF.Check SPPH's competition here
DCHPF vs OMHE Comparison April 2026
DCHPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCHPF stands at 5.3B. In comparison, OMHE has a market cap of 29.3K. Regarding current trading prices, DCHPF is priced at $46.90, while OMHE trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCHPF currently has a P/E ratio of -151.29, whereas OMHE's P/E ratio is N/A. In terms of profitability, DCHPF's ROE is -0.04%, compared to OMHE's ROE of +0.73%. Regarding short-term risk, DCHPF is less volatile compared to OMHE. This indicates potentially lower risk in terms of short-term price fluctuations for DCHPF.Check OMHE's competition here
DCHPF vs SCRCQ Comparison April 2026
DCHPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCHPF stands at 5.3B. In comparison, SCRCQ has a market cap of 14.1K. Regarding current trading prices, DCHPF is priced at $46.90, while SCRCQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCHPF currently has a P/E ratio of -151.29, whereas SCRCQ's P/E ratio is -0.01. In terms of profitability, DCHPF's ROE is -0.04%, compared to SCRCQ's ROE of +1.63%. Regarding short-term risk, DCHPF is less volatile compared to SCRCQ. This indicates potentially lower risk in terms of short-term price fluctuations for DCHPF.Check SCRCQ's competition here
DCHPF vs TSTS Comparison April 2026
DCHPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCHPF stands at 5.3B. In comparison, TSTS has a market cap of 12.8K. Regarding current trading prices, DCHPF is priced at $46.90, while TSTS trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCHPF currently has a P/E ratio of -151.29, whereas TSTS's P/E ratio is N/A. In terms of profitability, DCHPF's ROE is -0.04%, compared to TSTS's ROE of +2.32%. Regarding short-term risk, DCHPF is less volatile compared to TSTS. This indicates potentially lower risk in terms of short-term price fluctuations for DCHPF.Check TSTS's competition here
DCHPF vs IXSBF Comparison April 2026
DCHPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCHPF stands at 5.3B. In comparison, IXSBF has a market cap of 12.6K. Regarding current trading prices, DCHPF is priced at $46.90, while IXSBF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCHPF currently has a P/E ratio of -151.29, whereas IXSBF's P/E ratio is -0.01. In terms of profitability, DCHPF's ROE is -0.04%, compared to IXSBF's ROE of +1.90%. Regarding short-term risk, DCHPF is less volatile compared to IXSBF. This indicates potentially lower risk in terms of short-term price fluctuations for DCHPF.Check IXSBF's competition here
DCHPF vs VIAP Comparison April 2026
DCHPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCHPF stands at 5.3B. In comparison, VIAP has a market cap of 10.3K. Regarding current trading prices, DCHPF is priced at $46.90, while VIAP trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCHPF currently has a P/E ratio of -151.29, whereas VIAP's P/E ratio is -0.05. In terms of profitability, DCHPF's ROE is -0.04%, compared to VIAP's ROE of +0.65%. Regarding short-term risk, DCHPF is less volatile compared to VIAP. This indicates potentially lower risk in terms of short-term price fluctuations for DCHPF.Check VIAP's competition here
DCHPF vs ALST Comparison April 2026
DCHPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCHPF stands at 5.3B. In comparison, ALST has a market cap of 8.4K. Regarding current trading prices, DCHPF is priced at $46.90, while ALST trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCHPF currently has a P/E ratio of -151.29, whereas ALST's P/E ratio is N/A. In terms of profitability, DCHPF's ROE is -0.04%, compared to ALST's ROE of +0.07%. Regarding short-term risk, DCHPF and ALST have similar daily volatility (0.00).Check ALST's competition here
DCHPF vs HTPRF Comparison April 2026
DCHPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCHPF stands at 5.3B. In comparison, HTPRF has a market cap of 8.2K. Regarding current trading prices, DCHPF is priced at $46.90, while HTPRF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCHPF currently has a P/E ratio of -151.29, whereas HTPRF's P/E ratio is N/A. In terms of profitability, DCHPF's ROE is -0.04%, compared to HTPRF's ROE of +0.09%. Regarding short-term risk, DCHPF is less volatile compared to HTPRF. This indicates potentially lower risk in terms of short-term price fluctuations for DCHPF.Check HTPRF's competition here
DCHPF vs HBOSF Comparison April 2026
DCHPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCHPF stands at 5.3B. In comparison, HBOSF has a market cap of 7.8K. Regarding current trading prices, DCHPF is priced at $46.90, while HBOSF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCHPF currently has a P/E ratio of -151.29, whereas HBOSF's P/E ratio is 0.03. In terms of profitability, DCHPF's ROE is -0.04%, compared to HBOSF's ROE of +6.69%. Regarding short-term risk, DCHPF and HBOSF have similar daily volatility (0.00).Check HBOSF's competition here
DCHPF vs WPHM Comparison April 2026
DCHPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCHPF stands at 5.3B. In comparison, WPHM has a market cap of 7.7K. Regarding current trading prices, DCHPF is priced at $46.90, while WPHM trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCHPF currently has a P/E ratio of -151.29, whereas WPHM's P/E ratio is N/A. In terms of profitability, DCHPF's ROE is -0.04%, compared to WPHM's ROE of -1.56%. Regarding short-term risk, DCHPF and WPHM have similar daily volatility (0.00).Check WPHM's competition here
DCHPF vs PXYN Comparison April 2026
DCHPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCHPF stands at 5.3B. In comparison, PXYN has a market cap of 6.3K. Regarding current trading prices, DCHPF is priced at $46.90, while PXYN trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCHPF currently has a P/E ratio of -151.29, whereas PXYN's P/E ratio is N/A. In terms of profitability, DCHPF's ROE is -0.04%, compared to PXYN's ROE of -0.20%. Regarding short-term risk, DCHPF is less volatile compared to PXYN. This indicates potentially lower risk in terms of short-term price fluctuations for DCHPF.Check PXYN's competition here
DCHPF vs IYXI Comparison April 2026
DCHPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCHPF stands at 5.3B. In comparison, IYXI has a market cap of 5.2K. Regarding current trading prices, DCHPF is priced at $46.90, while IYXI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCHPF currently has a P/E ratio of -151.29, whereas IYXI's P/E ratio is N/A. In terms of profitability, DCHPF's ROE is -0.04%, compared to IYXI's ROE of +1.71%. Regarding short-term risk, DCHPF and IYXI have similar daily volatility (0.00).Check IYXI's competition here
DCHPF vs RBII Comparison April 2026
DCHPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCHPF stands at 5.3B. In comparison, RBII has a market cap of 5K. Regarding current trading prices, DCHPF is priced at $46.90, while RBII trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCHPF currently has a P/E ratio of -151.29, whereas RBII's P/E ratio is N/A. In terms of profitability, DCHPF's ROE is -0.04%, compared to RBII's ROE of -0.04%. Regarding short-term risk, DCHPF is less volatile compared to RBII. This indicates potentially lower risk in terms of short-term price fluctuations for DCHPF.Check RBII's competition here
DCHPF vs CXBS Comparison April 2026
DCHPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCHPF stands at 5.3B. In comparison, CXBS has a market cap of 2.7K. Regarding current trading prices, DCHPF is priced at $46.90, while CXBS trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCHPF currently has a P/E ratio of -151.29, whereas CXBS's P/E ratio is N/A. In terms of profitability, DCHPF's ROE is -0.04%, compared to CXBS's ROE of +0.00%. Regarding short-term risk, DCHPF is less volatile compared to CXBS. This indicates potentially lower risk in terms of short-term price fluctuations for DCHPF.Check CXBS's competition here
DCHPF vs NEWG Comparison April 2026
DCHPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCHPF stands at 5.3B. In comparison, NEWG has a market cap of 2.3K. Regarding current trading prices, DCHPF is priced at $46.90, while NEWG trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCHPF currently has a P/E ratio of -151.29, whereas NEWG's P/E ratio is N/A. In terms of profitability, DCHPF's ROE is -0.04%, compared to NEWG's ROE of +0.40%. Regarding short-term risk, DCHPF is less volatile compared to NEWG. This indicates potentially lower risk in terms of short-term price fluctuations for DCHPF.Check NEWG's competition here
DCHPF vs FSPM Comparison April 2026
DCHPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCHPF stands at 5.3B. In comparison, FSPM has a market cap of 1.3K. Regarding current trading prices, DCHPF is priced at $46.90, while FSPM trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCHPF currently has a P/E ratio of -151.29, whereas FSPM's P/E ratio is N/A. In terms of profitability, DCHPF's ROE is -0.04%, compared to FSPM's ROE of N/A. Regarding short-term risk, DCHPF and FSPM have similar daily volatility (0.00).Check FSPM's competition here
DCHPF vs GRPI Comparison April 2026
DCHPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCHPF stands at 5.3B. In comparison, GRPI has a market cap of 1K. Regarding current trading prices, DCHPF is priced at $46.90, while GRPI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCHPF currently has a P/E ratio of -151.29, whereas GRPI's P/E ratio is -0.02. In terms of profitability, DCHPF's ROE is -0.04%, compared to GRPI's ROE of +0.09%. Regarding short-term risk, DCHPF and GRPI have similar daily volatility (0.00).Check GRPI's competition here
DCHPF vs KIARF Comparison April 2026
DCHPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCHPF stands at 5.3B. In comparison, KIARF has a market cap of 442. Regarding current trading prices, DCHPF is priced at $46.90, while KIARF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCHPF currently has a P/E ratio of -151.29, whereas KIARF's P/E ratio is N/A. In terms of profitability, DCHPF's ROE is -0.04%, compared to KIARF's ROE of -1.47%. Regarding short-term risk, DCHPF is less volatile compared to KIARF. This indicates potentially lower risk in terms of short-term price fluctuations for DCHPF.Check KIARF's competition here
DCHPF vs ACGJ Comparison April 2026
DCHPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCHPF stands at 5.3B. In comparison, ACGJ has a market cap of 324. Regarding current trading prices, DCHPF is priced at $46.90, while ACGJ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCHPF currently has a P/E ratio of -151.29, whereas ACGJ's P/E ratio is -0.00. In terms of profitability, DCHPF's ROE is -0.04%, compared to ACGJ's ROE of N/A. Regarding short-term risk, DCHPF and ACGJ have similar daily volatility (0.00).Check ACGJ's competition here
DCHPF vs MDVLQ Comparison April 2026
DCHPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCHPF stands at 5.3B. In comparison, MDVLQ has a market cap of 161. Regarding current trading prices, DCHPF is priced at $46.90, while MDVLQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCHPF currently has a P/E ratio of -151.29, whereas MDVLQ's P/E ratio is N/A. In terms of profitability, DCHPF's ROE is -0.04%, compared to MDVLQ's ROE of -2.39%. Regarding short-term risk, DCHPF is less volatile compared to MDVLQ. This indicates potentially lower risk in terms of short-term price fluctuations for DCHPF.Check MDVLQ's competition here
DCHPF vs ISHI Comparison April 2026
DCHPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCHPF stands at 5.3B. In comparison, ISHI has a market cap of 5. Regarding current trading prices, DCHPF is priced at $46.90, while ISHI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCHPF currently has a P/E ratio of -151.29, whereas ISHI's P/E ratio is N/A. In terms of profitability, DCHPF's ROE is -0.04%, compared to ISHI's ROE of N/A. Regarding short-term risk, DCHPF is less volatile compared to ISHI. This indicates potentially lower risk in terms of short-term price fluctuations for DCHPF.Check ISHI's competition here
DCHPF vs SYNI Comparison April 2026
DCHPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCHPF stands at 5.3B. In comparison, SYNI has a market cap of 3. Regarding current trading prices, DCHPF is priced at $46.90, while SYNI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCHPF currently has a P/E ratio of -151.29, whereas SYNI's P/E ratio is -0.00. In terms of profitability, DCHPF's ROE is -0.04%, compared to SYNI's ROE of N/A. Regarding short-term risk, DCHPF and SYNI have similar daily volatility (0.00).Check SYNI's competition here
DCHPF vs GHTI Comparison April 2026
DCHPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCHPF stands at 5.3B. In comparison, GHTI has a market cap of 0. Regarding current trading prices, DCHPF is priced at $46.90, while GHTI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCHPF currently has a P/E ratio of -151.29, whereas GHTI's P/E ratio is N/A. In terms of profitability, DCHPF's ROE is -0.04%, compared to GHTI's ROE of N/A. Regarding short-term risk, DCHPF is less volatile compared to GHTI. This indicates potentially lower risk in terms of short-term price fluctuations for DCHPF.Check GHTI's competition here
DCHPF vs MDSI Comparison April 2026
DCHPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCHPF stands at 5.3B. In comparison, MDSI has a market cap of 0. Regarding current trading prices, DCHPF is priced at $46.90, while MDSI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCHPF currently has a P/E ratio of -151.29, whereas MDSI's P/E ratio is N/A. In terms of profitability, DCHPF's ROE is -0.04%, compared to MDSI's ROE of N/A. Regarding short-term risk, DCHPF and MDSI have similar daily volatility (0.00).Check MDSI's competition here
DCHPF vs TFSHF Comparison April 2026
DCHPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCHPF stands at 5.3B. In comparison, TFSHF has a market cap of 0. Regarding current trading prices, DCHPF is priced at $46.90, while TFSHF trades at $1.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCHPF currently has a P/E ratio of -151.29, whereas TFSHF's P/E ratio is N/A. In terms of profitability, DCHPF's ROE is -0.04%, compared to TFSHF's ROE of N/A. Regarding short-term risk, DCHPF and TFSHF have similar daily volatility (0.00).Check TFSHF's competition here
DCHPF vs MMCWF Comparison April 2026
DCHPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCHPF stands at 5.3B. In comparison, MMCWF has a market cap of 0. Regarding current trading prices, DCHPF is priced at $46.90, while MMCWF trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCHPF currently has a P/E ratio of -151.29, whereas MMCWF's P/E ratio is N/A. In terms of profitability, DCHPF's ROE is -0.04%, compared to MMCWF's ROE of N/A. Regarding short-term risk, DCHPF and MMCWF have similar daily volatility (0.00).Check MMCWF's competition here